2026-10046NoticeWallet

Drug Maker Seeks Tax Break for Opdualag Production

Published Date: 5/20/2026

Notice

Summary

Patheon Manufacturing Services in Greenville, NC wants to make a cancer-fighting drug called Opdualag using special foreign materials without paying extra import taxes. This change could speed up production and save money by using Foreign-Trade Zone benefits. People have until June 29, 2026, to share their thoughts before the plan gets the green light.

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

Opdualag Production Allowed in FTZ 214

Patheon Manufacturing Services filed to produce Opdualag (pre-filled syringes containing Relatlimab and Nivolumab) at its facility in FTZ 214 in Greenville, North Carolina. The notice states the proposed finished product is duty-free when admitted under FTZ procedures. Public comments are invited through June 29, 2026.

Section 301 Duties May Still Apply

The notice states certain materials/components may be subject to duties under section 301 of the Trade Act of 1974 depending on country of origin, and applicable section 301 decisions require such merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
5/20/2026

Department and Agencies

Department
Independent Agency
Agency
Commerce Department
Foreign-Trade Zones Board
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register